特立帕肽
骨质疏松症
德诺苏马布
骨矿物
医学
骨吸收
骨密度保护剂
骨重建
维生素D与神经学
雷奈酸锶
内科学
骨密度
维生素D缺乏
骨折
双能X射线吸收法
内分泌学
骨愈合
生物信息学
外科
生物
放射科
作者
John R. Dimar,Joseph M. Lane,Ronald A. Lehman,Paul A. Anderson
出处
期刊:PubMed
日期:2021-01-01
卷期号:70: 527-536
被引量:2
摘要
Osteoporosis is a skeletal condition characterized by decreased bone mineral density and poor bone quality with resultant greater fracture risk. There has been a focus on bone mineral density deficiency, which is easily measured with dual-energy x-ray absorptiometry and managed with pharmaceutic medications. More recently, impaired bone quality independent of bone mineral density has been recognized as a potential cause of fragility fracture and poor bone healing. Many conditions lead to poor bone quality; the most common is vitamin D deficiency and others are genetic causes and other nutritional deficits. In addition, the cellular and molecular changes associated with osteoporosis are being investigated and are potential targets for treatment. Treatment of patients with poor bone health include nutritional supplementation with vitamin D and calcium, weight-bearing exercises, and antiosteoporotic medications when warranted. Antiosteoporotic medications include antiresorptive drugs such as diphosphonate and denosumab that inhibit osteoclastic bone resorption. Anabolic agents such as teriparatide, abaloparatide, and romosozumab stimulate osteoblastic differentiation and bone formation. All these agents are effective in reducing fracture risk.
科研通智能强力驱动
Strongly Powered by AbleSci AI